CLINICAL TRIALS PROFILE FOR VIEKIRA XR

All Clinical Trials for VIEKIRA XR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02461745 ↗	Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO	Completed	AbbVie	Phase 4	2015-06-01	This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).
NCT02461745 ↗	Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO	Completed	Kaiser Permanente	Phase 4	2015-06-01	This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	AbbVie	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	Merck Sharp & Dohme Corp.	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	Patient-Centered Outcomes Research Institute	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	University of Florida	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
NCT02946034 ↗	Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C	Completed	AbbVie	Phase 4	2017-02-01	Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

Clinical Trial Conditions for VIEKIRA XR

Condition Name

Condition Name for VIEKIRA XR
Intervention	Trials
Chronic Hepatitis C	2
Chronic Kidney Disease	1
Hepatitis C, Chronic	1

Condition MeSH

Condition MeSH for VIEKIRA XR
Intervention	Trials
Hepatitis C, Chronic	3
Hepatitis C	3
Hepatitis A	3
Hepatitis	3

Clinical Trial Locations for VIEKIRA XR

Trials by Country

Trials by Country for VIEKIRA XR
Location	Trials
United States	25

Trials by US State

Trials by US State for VIEKIRA XR
Location	Trials
Massachusetts	2
California	2
New Mexico	1
Nebraska	1
Missouri	1

Clinical Trial Progress for VIEKIRA XR

Clinical Trial Phase

Clinical Trial Phase for VIEKIRA XR
Clinical Trial Phase	Trials
Phase 4	3

Clinical Trial Status

Clinical Trial Status for VIEKIRA XR
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for VIEKIRA XR

Sponsor Name

Sponsor Name for VIEKIRA XR
Sponsor	Trials
AbbVie	3
Kaiser Permanente	1
Merck Sharp & Dohme Corp.	1

Sponsor Type

Sponsor Type for VIEKIRA XR
Sponsor	Trials
Industry	4
Other	4

VIEKIRA XR Market Analysis and Financial Projection

Last updated: May 1, 2026

VIEKIRA XR (ombitasvir/paritaprevir/ritonavir with dasabuvir) — Clinical-Phase Update and Market Forecast

What is VIEKIRA XR and what is its current clinical status?

VIEKIRA XR is an oral, direct-acting antiviral (DAA) regimen for chronic hepatitis C (CHC) that combines:

• Ombitasvir
• Paritaprevir
• Ritonavir
• Dasabuvir
  (“VIEKIRA XR” is the extended-release fixed-dose formulation of this regimen.)

Clinical development and phase state

VIEKIRA XR’s development and approvals are mature, with the regimen already established through the pivotal DAA-era trials and label expansion work conducted during the mid-to-late 2010s. No current evidence supports an active, late-stage (Phase 3) program involving VIEKIRA XR as a standalone product in the public trial registries and literature record that is typically tracked for ongoing Phase 3 readouts.

Practical readout: what matters for current clinical decision-making

For commercialization today, VIEKIRA XR’s clinical footprint is dominated by:

• Real-world use patterns for genotype-specific and treatment-experienced populations during the earlier DAA waves.
• Comparative displacement as newer, pangenotypic, shorter-duration regimens took share (e.g., sofosbuvir-based pangenotypic platforms).

Key clinical position in the DAA landscape

VIEKIRA XR is not a “new entrant.” Its clinical value proposition has shifted from “latest available DAA” to “remaining use in specific payer/provider formularies,” mostly tied to:

• Genotype and prior treatment status alignment
• Drug-drug interaction management (ritonavir component)
• Formulary dynamics and contracting

What does the market look like for VIEKIRA XR today?

VIEKIRA XR sits in the mature global CHC market, where demand has been structurally shaped by:

• High uptake of DAAs following broad guideline adoption in the 2010s
• Progressive transition to shorter, pangenotypic regimens
• Ongoing diagnosis and treatment targets under public health elimination strategies

Demand structure

The CHC DAA market is no longer expanding in the way it did during initial DAA scale-up. Growth has shifted to:

• Treatment expansion in previously untreated segments
• Re-treatment needs and churn from diagnosis pipeline
• Region-specific payer coverage and access cycles

Against that backdrop, a genotype- or regimen-complexity-sensitive product like VIEKIRA XR faces:

• Formulaic replacement by pangenotypic options in many formularies
• Net share dilution even if absolute CHC treatment volumes rise

Competitive set and substitution pressure

VIEKIRA XR competes directly with:

• Pangenotypic regimens that reduce genotype testing and simplify treatment pathways
• Shortened-duration strategies that improve patient adherence and payer preference

This substitution dynamic is why mature DAAs commonly show declining unit share over time even when overall CHC treatment volume remains resilient.

What is the forward projection for VIEKIRA XR (revenue and demand)?

Base-case market trajectory

The forecast for VIEKIRA XR is best modeled as a declining share-of-market product with residual demand:

• Declining unit share due to payer and prescriber preference for simplified, pangenotypic options
• Residual usage sustained by contracts, known clinical practice patterns, and drug availability in certain settings

Projection logic (what will drive the line)

VIEKIRA XR’s revenue trajectory over the next several years is primarily determined by:

• Share loss versus pangenotypic competitors
• Country-by-country formulary lock-in (some markets keep older regimens longer under existing contracting)
• Patient cohort continuity (remaining treatment cohorts that map to the regimen’s label positioning)
• Manufacturing and channel continuity (ability to supply without disruption)

Directional forecast

Given the maturity of VIEKIRA XR and the DAA market’s structural shift toward pangenotypic, simplified therapy, the base-case projection is:

• Declining revenue and volume in most major markets
• Lower single-digit to mid-single-digit CAGR decline typical for mature specialized products, with variability driven by local contracting and elimination program pacing

The market forecast direction is consistent with the widely documented pattern of older DAA regimens losing share to newer pangenotypic DAAs in both competitive and public procurement settings.

What are the biggest risks to the VIEKIRA XR forecast?

1. Faster-than-expected formulary migration
   If payers move aggressively to pangenotypic regimens, VIEKIRA XR demand compresses quickly.

2. DAA contracting renegotiation cycles
   Public tenders often re-price based on lowest-cost supply and updated guideline concordance.

3. Drug-drug interaction and regimen simplification trends
   As clinicians shift to regimens with fewer interaction constraints, ritonavir-containing strategies lose preference.

What are the main upsides?

1. Remaining payer cohorts with established treatment pathways
   In some geographies, existing protocols continue to use established DAAs while switching is still in progress.

2. Inventory and channel timing effects
   Reordering and contract fill rates can create temporary revenue stabilizations even during structural share erosion.

How should investors and R&D leaders interpret VIEKIRA XR’s clinical and market profile?

VIEKIRA XR is best treated as:

• A mature product with a contracting-driven revenue curve
• A diminished growth asset
• A clinical “known quantity” with limited probability of new major trial-driven demand inflection

For R&D strategy, the relevant takeaway is that the CHC market rewards:

• Simplification (pangenotypic)
• Shorter treatment courses
• Lower interaction management burden

Regulatory and label context that still affects demand

Demand for VIEKIRA XR remains sensitive to label alignment by:

• Genotype categorization
• Prior treatment status
• Liver disease severity constraints and eligibility
• Concomitant medication interaction constraints tied to ritonavir

These factors usually intensify substitution pressure as guidelines increasingly support simplified regimens.

---

Key Takeaways

• VIEKIRA XR is in the mature phase of the CHC DAA lifecycle; the regimen’s major trial readouts are already past, and the current competitive environment is dominated by pangenotypic substitution.
• Market demand is structurally share-erosive as payers and clinicians move to simpler regimens, even if CHC treatment volumes in absolute terms continue via diagnosis and elimination programs.
• Base-case outlook is declining revenue/volume, with the slope driven by formulary migration speed and contracting cycles rather than new clinical differentiation.
• Forecast risks are primarily payer/tender behavior and interaction-driven regimen preference shifts.

---

FAQs

1) Is VIEKIRA XR still being evaluated in new late-stage trials?

No active Phase 3 program evidence is supported in the publicly trackable record for a new VIEKIRA XR-led late-stage readout.

2) Why does VIEKIRA XR face substitution pressure despite established clinical efficacy?

The DAA market has moved toward pangenotypic, simplified regimens, and payer formularies typically follow that shift.

3) What label features most influence ongoing use?

Genotype alignment, prior treatment status eligibility, and drug-drug interaction constraints related to ritonavir.

4) What is the primary driver of near-term revenue volatility for mature DAAs like VIEKIRA XR?

Public and commercial contracting refill cycles and tender-driven re-pricing.

5) What should be the benchmark comparator in market modeling?

Pangenotypic DAA platforms that reduce genotype testing needs and simplify treatment pathway management.

---

References

[1] FDA. “VIEKIRA XR (ombitasvir, paritaprevir, ritonavir, and dasabuvir) prescribing information.” U.S. Food and Drug Administration.
[2] European Medicines Agency (EMA). “Viekira XR: Summary of Product Characteristics.” European Medicines Agency.
[3] AASLD/IDSA. “HCV Guidance: Recommendations for testing, managing, and treating hepatitis C.” American Association for the Study of Liver Diseases and Infectious Diseases Society of America.
[4] World Health Organization (WHO). “Global hepatitis report” and hepatitis elimination progress materials. World Health Organization.
[5] ClinicalTrials.gov. VIEKIRA XR and ombitasvir/paritaprevir/ritonavir/dasabuvir search results. U.S. National Library of Medicine.